US Stock MarketDetailed Quotes
ROIV Roivant Sciences
- 12.530
- +0.710+6.01%
Close Nov 22 16:00 ET
- 12.500
- -0.030-0.24%
Post 18:56 ET
9.12BMarket Cap2.15P/E (TTM)
12.570High11.780Low11.36MVolume11.830Open11.820Pre Close139.46MTurnover3.06%Turnover Ratio2.40P/E (Static)727.95MShares13.05552wk High1.77P/B4.66BFloat Cap8.61152wk Low--Dividend TTM371.77MShs Float16.760Historical High--Div YieldTTM6.68%Amplitude2.520Historical Low12.274Avg Price1Lot Size
About Roivant Sciences Company
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Company Profile
SymbolROIV
Company NameRoivant Sciences
Listing DateDec 14, 2020
Founded2021
CEOMr. Matthew Gline
MarketNASDAQ
Employees908
Fiscal Year Ends03-31
Address50 Broadway,7th Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeSW1H 0BD
Phone44-207-400-3347
Websitehttp://www.roivant.com
Company Executives
- Name
- Position
- Salary
- Matthew Gline
- Chief Executive Officer and Director
- 738.19K
- Dr. Mayukh Sukhatme
- President, Chief Investment Officer and Director
- 574.56K
- Richard Pulik
- Chief Financial Officer
- 5.15M
- Rakhi Kumar
- Chief Accounting Officer
- 4.33M
- Dr. Eric Venker, M.D.,Pharm.D.
- President and Chief Operating Officer
- --
- Ilan Oren
- Chairman of the Board
- 488.49K
- Melissa B. Epperly
- Independent Director
- 444.24K
- Meghan M. Fitzgerald, Ph.
- Independent Director
- 941.68K
- Keith Manchester, M.D.
- Independent Director
- 442.59K
- James C. Momtazee
- Independent Director
- 459.24K
- Daniel Gold
- Independent Director
- 449.24K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data